Myriad Genetics will announce Q3 2025 earnings on Nov. 3 at 4:30 PM ET, hosting a conference call afterward.
Quiver AI Summary
Myriad Genetics, Inc. announced that it will hold its third quarter 2025 earnings conference call on November 3, 2025, at 4:30 pm ET. The company will release its quarterly earnings after the market closes on the same day, and management will provide updates on financial performance and business operations during the call. Investors can access a live webcast on Myriad’s Investor Relations website, and those wishing to join via telephone must register to receive a dial-in number and PIN. An archived version of the call will also be available afterward. Myriad Genetics specializes in molecular diagnostic testing and aims to improve health outcomes through precision medicine.
Potential Positives
- Myriad Genetics is positioned as a leader in the growing field of molecular diagnostic testing and precision medicine, indicating strong market relevance.
- The timing of the earnings conference call, closely following the end of the financial quarter, suggests transparency and proactive communication with investors.
- The provision of a live webcast and archived access demonstrates a commitment to investor engagement and accessibility of information.
Potential Negatives
- None
FAQ
When will Myriad Genetics announce its Q3 2025 earnings?
Myriad Genetics will announce its Q3 2025 earnings on November 3, 2025, after the market closes.
What time is the Myriad Genetics Q3 earnings conference call?
The conference call will be held at 4:30 pm ET on November 3, 2025.
Where can I access the Myriad Genetics conference call webcast?
The webcast can be accessed on Myriad’s Investor Relations website at investor.myriad.com.
How can I participate in the conference call by phone?
To join by phone, you must register online to receive a dial-in number and unique PIN.
What is the focus of Myriad Genetics' third quarter earnings call?
The call will focus on a financial overview and business update for Q3 2025.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MYGN Hedge Fund Activity
We have seen 126 institutional investors add shares of $MYGN stock to their portfolio, and 110 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP removed 4,592,264 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $24,384,921
- DISCIPLINED GROWTH INVESTORS INC /MN removed 3,979,736 shares (-84.1%) from their portfolio in Q2 2025, for an estimated $21,132,398
- EARNEST PARTNERS LLC removed 3,977,292 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $21,119,420
- MORGAN STANLEY added 2,939,498 shares (+182.1%) to their portfolio in Q2 2025, for an estimated $15,608,734
- SEI INVESTMENTS CO removed 2,526,761 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $13,417,100
- ARTISAN PARTNERS LIMITED PARTNERSHIP removed 2,277,256 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $12,092,229
- BANK OF AMERICA CORP /DE/ removed 2,214,609 shares (-84.2%) from their portfolio in Q2 2025, for an estimated $11,759,573
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MYGN Analyst Ratings
Wall Street analysts have issued reports on $MYGN in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 05/15/2025
- Goldman Sachs issued a "Buy" rating on 05/07/2025
- Raymond James issued a "Outperform" rating on 05/07/2025
To track analyst ratings and price targets for $MYGN, check out Quiver Quantitative's $MYGN forecast page.
$MYGN Price Targets
Multiple analysts have issued price targets for $MYGN recently. We have seen 6 analysts offer price targets for $MYGN in the last 6 months, with a median target of $7.5.
Here are some recent targets:
- Sung Ji Nam from Scotiabank set a target price of $6.0 on 05/21/2025
- Dave Weiner from Piper Sandler set a target price of $9.0 on 05/15/2025
- Brandon Couillard from Wells Fargo set a target price of $6.0 on 05/08/2025
- Matthew Sykes from Goldman Sachs set a target price of $8.0 on 05/07/2025
- Lu Li from UBS set a target price of $7.0 on 05/07/2025
- Andrew Cooper from Raymond James set a target price of $10.0 on 05/07/2025
Full Release
SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings conference call at 4:30 pm ET on Monday, Nov. 3, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2025.
A live webcast of the conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com . To participate in the live conference call via telephone, please register here . Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit
www.myriad.com
.
Investor Contact
Matt Scalo
(801) 584-3532
[email protected]
Media Contact
Kate Schraml
(224) 875-4493
[email protected]
